Paratek Pharmaceuticals Inc. (PRTK) and Allergan (AGN) announced Monday morning that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy endpoints.
from RTT - Before the Bell http://ift.tt/2nrx2dA
via IFTTT
No comments:
Post a Comment